NCT01588769View on ClinicalTrials.gov

A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

April 30, 2013

Conditions
Glioblastoma Multiforme
Interventions
BIOLOGICAL

ALECSAT cell based immunotherapy

I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.

Trial Locations (1)

DK 2100

Department of Neurosurgery, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

CytoVac A/S

INDUSTRY

NCT01588769 - A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | Biotech Hunter | Biotech Hunter